biOasis Technologies Ord Shs V.BTI.H

Glioblastoma market US$4.2 billion in 2028

[prophetoffactz]

BTI's presentation says US$2.14 billion in 2020 growing at 8.8 through 2028.

That's US$4.2 billion per year in 2028.

Not bad for a lead asset that is already in clinical trials with safety risk potentially well addressed already and efficacy data from other preclinical and clinical trials to build upon.

That's a C$5.67 billion market in 2028 in Canadian dollars.

BTI may be merging with another undervalued assets reducing dilution.

Then there is the EGF assets too, etc.

[JDavenport]

It will be years before xB3 versions of Midatech's drugs can be designed, put through preclinical studies and then clinical trials. Over five years. That's a minimum. Add that to the 15 years that Bioasis shareholders have.... Never mind. jd

[prophetoffactz]

"It will be years before xB3 versions of Midatech's drugs can be designed, put through preclinical studies and then clinical trials. Over five years. That's a minimum." That's the biotech life. Certain catalysts can also lead to early value realization for shareholders. Biodexa may have an emerging compelling position in the space.   BTI has already been working on xB3

[JDavenport]

Bwah hahaha. Gobbledeegook, poof, copied, pasted, and undigested. And yet all thos drugs like Herceptin that get a free ride because they require no R&D to speak of, will go to somebody else and Bioasis shareholders will lose any meaningful ownership in anything. It's fun to watch you, though. jd

[prophetoffactz]

"It will be years before xB3 versions of Midatech's drugs can be designed, put through preclinical studies and then clinical trials. Over five years. That's a minimum." Given the potential market: "That's a C$5.67 billion market in 2028 in Canadian dollars." Could Biodexa be seen as having a compelling and leading potential solution in the next 1-2 years. With

[JDavenport]

In the next 4 to 5 years, poof. And the minute that Biodexa publicly announces xB3 versions of their drugs, then the market will instantly discount the value of their existing non-xB3 versions. The market will make the correct assumption that the non-xB3 versions are dead and worthless, and that shareholders will have to wait years and years for the new ones.  Not that the market is giving

[zwerp2000]

Could Biodexa be seen as having a compelling and leading potential solution in the next 1-2 years. With even a 10% probability of a leading poisition that could mean a huge payout early on.   NO!! That is why they were sold for nothing. Your posts are just ridiculous.